ZyVersa Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 31, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 31, 2026

ZVSA$0.12+8.7%Stored close · as of Jul 8, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Signatures

Pursuant to the requirements of Section 13 and 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned thereunto duly authorized.

	ZYVERSA THERAPEUTICS, INC.
Date: March 31, 2026	/s/ Stephen C. Glover
	Stephen C. Glover
	Chief Executive Officer
	(Principal Executive Officer)
Date: March 31, 2026	/s/ Peter Wolfe
	Peter Wolfe
	Chief Financial Officer
	(Principal Financial and Accounting Officer)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.